Research progress in prognosis of diffuse large B-cell lymphoma / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 129-134, 2017.
Article
em Zh
| WPRIM
| ID: wpr-509665
Biblioteca responsável:
WPRO
ABSTRACT
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma with highly heterogeneous both clinically and biologically. So the prediction for prognosis of DLBCL and identifying patients with high risk are coming into the focus of the 58th American Society of Hematology (ASH) Annual Meeting. International prognostic index (IPI) risk model is widely known as the powerful prognostic indicator for DLBCL but in rituximab-era is challenged by a variety of new prognosis systems. Biological markers and mutation and expression of genes play an important role in the pathogenesis and progression of lymphoma, and its prognostic value draw much more attention. The prognostic factors of DLBCL, specific types, such as primary breast DLBCL, intravascular large B-cell lymphoma, the presence of a DLBCL component in a follicular lymphoma and relapsed/refractory DLBCL have been paid more attention in this meeting.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Prognostic_studies
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2017
Tipo de documento:
Article